橙子视频app安卓下载,91橙子视频,橙子视频旧款,橙子视频在线官网

PFI-1 is a novel potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family proteins BRD2 and BRD4 with IC50 of ~98 nM and 220 nM respectively. Co-crystal structures showed that PFI-1 acts as an acetyl-lysine (Kac) mimetic inhibitor efficiently occupying the Kac in BRD2 and BRD4. It has an EC₅₀ of 1.89 μM for the inhibition of IL6 production from human blood mononuclear cells stimulated by LPS. PFI-1 induces dose-dependent reduction of cell viability in T4302 CD133+ cells, inhibits the proliferation of three NET cell lines (Bon-1 derived from a pancreatic NET, and H727 and H720 derived from lung NETs). It was also shown that PFI-1 could significantly down-regulate Aurora B kinase, thus attenuating phosphorylation of the Aurora substrate H3S10.

How to Use:

• In vitro: PFI-1 was used at 10 µM final concentration in various in vitro assays.
• In vivo: PFI-1 could be dosed to rats by IV administration at 1 mg/kg once per day, or oral administration at 2 mg/kg once per day.

Reference:

1. 1. Fish PV, et al. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. (2012) J Med Chem. 55(22):9831-7.
2. 2. Picaud S, et al. PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains. (2013) Cancer Res. 73(11):3336-3346.

Products are for research use only. Not for human use.